2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Related Products

PDF 4.17 MB

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.

Phosphodiesterase (PDE) Isoform Specific Products:

Phosphodiesterase (PDE) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-146974
    PDE4-IN-9
    		Inhibitor
    PDE4-IN-9 (Compound 5j) is a potent inhibitor of PDE4. PDE4-IN-9 exhibits lower IC50 value (1.4 μM) against PDE4 than parent rolipram (2.0 μM) in in vitro enzyme assay. PDE4-IN-9 also displays good in vivo activity in animal models of asthma/COPD and sepsis induced by LPS.
    PDE4-IN-9
  • HY-162581
    FCPR16
    		Inhibitor
    FCPR16 is a Phosphodiesterase 4 (PDE4) inhibitor. FCPR16 increases the levels of cAMP in SH-SY5Y cells. FCPR16 can be used in the study of Parkinson's disease.
    FCPR16
  • HY-125050
    KCA-1490
    		Inhibitor
    KCA-1490 is a dual PDE3/4 inhibitor with IC50 values of 369 nM and 42 nM, respectively. KCA-1490 exhibits potent bronchodilatory and anti-inflammatory activity. KCA-1490 suppresses Histamine (HY-B1204)-induced bronchoconstriction in vivo, which is promising for research of asthma and chronic obstructive pulmonary disease (COPD).
    KCA-1490
  • HY-134937
    BC8-15
    		Inhibitor
    BC8-15 is a PDE inhibitor with IC50 values of 0.28, 0.22, and 6.46 µM for inhibiting PDE8A, PDE4A, and PDE7A, respectively. BC8-15 can enhance steroidogenesis in mouse Leydig cells.
    BC8-15
  • HY-170788
    PDE7A-IN-1
    		Inhibitor
    PDE7A-IN-1 (Compound 26) is an orally active PDE7A inhibitor with an IC50 value of 3.7 nM. PDE7A-IN-1 significantly improves bone mineral density by inhibiting the sclerostin (sclerostin) and is suitable for the study of osteoporosis and related bone metabolic diseases.
    PDE7A-IN-1
  • HY-12085S2
    (Rac)-Apremilast-d5
    (Rac)-Apremilast-d5 is a deuterium labeled (R)-Apremilast. (R)-Apremilast ((R)-CC-10004) is a enantiomer of Apremilast.
    (Rac)-Apremilast-d<sub>5</sub>
  • HY-155944
    Isbufylline
    		Inhibitor
    Isbufylline is a Phosphodiesterase inhibitor. Isbufylline is orally available. Isbufylline can be used in the research of respiratory diseases and inflammation such as asthma and pneumonia.
    Isbufylline
  • HY-135746R
    OR-1896 (Standard)
    		Inhibitor
    7-epi-Taxol (Standard) is the analytical standard of 7-epi-Taxol. This product is intended for research and analytical applications. 7-epi-Taxol is an active metabolite of taxol, with activity comparable to that of taxol against cell replication, promoting microtubule bundle formation and against microtubule depolymerization.
    OR-1896 (Standard)
  • HY-RS10206
    Pde12 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Pde12 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pde12 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Pde12 Mouse Pre-designed siRNA Set A
    Pde12 Mouse Pre-designed siRNA Set A
  • HY-B0763S1
    Ibudilast-d7
    		Inhibitor
    Ibudilast-d7 is the deuterium labeled Ibudilast. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia.
    Ibudilast-d<sub>7</sub>
  • HY-W700638A
    Benafentrine maleate
    		Inhibitor
    Benafentrine maleate is a platelet activating factor receptor (PAFR) antagonist and a PDE 4 inhibitor.
    Benafentrine maleate
  • HY-N13132
    Hellicoside
    		Inhibitor
    Hellicoside is a natural product that can be obtained from plantain. Hellicoside has inhibitory activity against cAMP phosphodiesterase and 5-lipoxygenase.
    Hellicoside
  • HY-N10149
    Nauclefine
    		Modulator
    Nauclefine is an indole alkaloid isolated from Nauclea officinalis. Nauclefine acts as a PDE3A modulator to induce cancer cell apoptosis through a PDE3A-SLFN12-dependent death pathway.
    Nauclefine
  • HY-B1726
    Phenacaine
    		Inhibitor
    Phenacaine (Holocaine) is a local agent that can suppress or relieve pain. Phenacaine inhibits the specific calmodulin-dependent stimulation of erythrocyte Ca2+-ATPase and cyclic nucleotide phosphodiesterases from brain and heart.
    Phenacaine
  • HY-N0014R
    Icariin (Standard)
    		Inhibitor
    Icariin (Standard) is the analytical standard of Icariin. This product is intended for research and analytical applications. Icariin is a flavonol glycoside. Icariin inhibits PDE5 and PDE4 activities with IC50s of 432 nM and 73.50 μM, respectively. Icariin also is a PPARα activator.
    Icariin (Standard)
  • HY-148625
    PDE9-IN-2
    		Inhibitor
    PDE9-IN-2 (compound 6) is a PDE9 inhibitor that improves heart failure.
    PDE9-IN-2
  • HY-90009AS1
    Tadalafil-13C2,d3-1
    Tadalafil-13C2,d3-1 (IC-351-13C2,d3-1) is the deuterium and 13C-labeled Tadalafil (HY-90009A). Tadalafil (IC-351) is a PDE5 inhibitor with an IC50 value of 1.8 nM.
    Tadalafil-13</sup>C<sub>2</sub>,d<sub>3</sub>-1
  • HY-125738
    Obscurolide A1
    		Inhibitor
    Obscurolide A1 is a Phosphodiesterase (PDE) inhibitor (IC50=8 mM) that can be obtained from Streptomyces viridochromogenes culture. Obscurolide A1 has the potential to study neurological and inflammatory diseases.
    Obscurolide A1
  • HY-145064
    Enpp-1-IN-6
    		Inhibitor
    Enpp-1-IN-6 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-6 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51).
    Enpp-1-IN-6
  • HY-18252S1
    Avanafil-13C5,15N,d2
    		Inhibitor
    Avanafil-13C5,15N,d2 is 15N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.
    Avanafil-<sup>13</sup>C<sub>5</sub>,<sup>15</sup>N,d<sub>2</sub>
Cat. No. Product Name / Synonyms Application Reactivity
Phosphodiesterase (PDE) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.